Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The Dutch National Health Care Institute (Zorginstituut Nederland) specified indication for one-way endobronchial valves that can be supported for coverage within basic health insurance package

In 2012, the Dutch National Health Care Institute (Zorginstituut Nederland, ZIN) assessed the application of one-way endobronchial valves for endobronchial lung volume reduction (LVR) in relation to satisfaction criteria of “state of science and practice”. At that time evidence was considered as insufficient to give a positive conclusion.

In 2016, the new evidence became available, and ZIN re-evaluated the procedure of LVR using one-way endobronchial valves. Based on current evidence ZIN considers that one-way endobronchial valves are effective in concerned indication and therefore fulfills the criteria of “state of science and practice”. Therefore, it can be a part of a basic health insurance package for patients with severe emphysema (III and IV GOLD stages) and insufficiency of drug treatment.

In accordance with the report, there are about 25-120 patients per year that can be treated with this procedure in the Netherlands.

This position entered into force on 14th of September, 2017.

See full-text position paper in Dutch here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.